[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2809349T1 - Imunogeni sestavek - Google Patents

Imunogeni sestavek

Info

Publication number
SI2809349T1
SI2809349T1 SI201331329T SI201331329T SI2809349T1 SI 2809349 T1 SI2809349 T1 SI 2809349T1 SI 201331329 T SI201331329 T SI 201331329T SI 201331329 T SI201331329 T SI 201331329T SI 2809349 T1 SI2809349 T1 SI 2809349T1
Authority
SI
Slovenia
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
SI201331329T
Other languages
English (en)
Inventor
Subhash Vinayak Kapre
Sambhaji Shankar Pisal
Original Assignee
Serum Institute Of India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Private Limited filed Critical Serum Institute Of India Private Limited
Publication of SI2809349T1 publication Critical patent/SI2809349T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SI201331329T 2012-01-30 2013-01-29 Imunogeni sestavek SI2809349T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN281MU2012 2012-01-30
EP13743463.5A EP2809349B1 (en) 2012-01-30 2013-01-29 Immunogenic composition
PCT/IB2013/050739 WO2013114268A1 (en) 2012-01-30 2013-01-29 Immunogenic composition

Publications (1)

Publication Number Publication Date
SI2809349T1 true SI2809349T1 (sl) 2019-03-29

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331329T SI2809349T1 (sl) 2012-01-30 2013-01-29 Imunogeni sestavek

Country Status (17)

Country Link
US (1) US9198977B2 (sl)
EP (1) EP2809349B1 (sl)
JP (1) JP6042455B2 (sl)
KR (1) KR101897317B1 (sl)
CN (1) CN104302315B (sl)
BR (1) BR112014018815B1 (sl)
CA (1) CA2863178C (sl)
DK (1) DK2809349T3 (sl)
ES (1) ES2707294T3 (sl)
HU (1) HUE040914T4 (sl)
MX (1) MX354103B (sl)
PT (1) PT2809349T (sl)
RU (1) RU2634405C2 (sl)
SG (1) SG11201404447WA (sl)
SI (1) SI2809349T1 (sl)
TR (1) TR201900778T4 (sl)
WO (1) WO2013114268A1 (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101351870B1 (ko) * 2005-06-27 2014-02-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
BR112015011722B1 (pt) * 2012-11-21 2022-08-09 Serum Institute Of India Ltd Método para preparar um polissacarídeo capsular de neisseria meningitidis x
CN105744951B (zh) 2013-08-24 2021-03-16 巴拉特生物技术国际有限公司 细菌疫苗及其制备方法
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
KR20240007690A (ko) 2015-06-08 2024-01-16 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제
EA039487B1 (ru) * 2015-07-04 2022-02-01 Бхарат Байотек Интернэшнл Лимитед Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
KR20190044663A (ko) 2016-09-02 2019-04-30 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
GEP20227408B (en) * 2017-05-05 2022-08-25 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
BR112019027182A2 (pt) * 2017-06-27 2020-06-30 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. nova composição de vacina conjugada de proteína - polissacarídeo multivalente e formulação da mesma
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise Inc MULTIVALENT PNEUMOCOCCAL GLYCOCONJUGATE VACCINES CONTAINING AN EMERGING 24F SEROTYPE
CN118078981A (zh) * 2024-04-26 2024-05-28 成都康华生物制品股份有限公司 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
PL1961426T3 (pl) * 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
KR101351870B1 (ko) * 2005-06-27 2014-02-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
EP1967204B1 (en) * 2005-09-01 2013-10-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccination including serogroup c meningococcus
JP5579387B2 (ja) * 2005-12-22 2014-08-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖類コンジュゲートを含むワクチン
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
JP5892944B2 (ja) * 2009-12-17 2016-03-23 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー コンジュゲートワクチンの製造における多糖の活性化のための化学試薬
BR112014029313A2 (pt) * 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x

Also Published As

Publication number Publication date
CA2863178A1 (en) 2013-08-08
MX354103B (es) 2018-02-13
RU2014134288A (ru) 2016-03-20
HUE040914T4 (hu) 2019-05-28
CA2863178C (en) 2021-04-06
JP2015509111A (ja) 2015-03-26
KR101897317B1 (ko) 2018-09-11
RU2634405C2 (ru) 2017-10-26
MX2014009250A (es) 2015-03-19
US9198977B2 (en) 2015-12-01
US20140377302A1 (en) 2014-12-25
BR112014018815A8 (pt) 2017-07-11
TR201900778T4 (tr) 2019-02-21
EP2809349B1 (en) 2018-12-19
CN104302315B (zh) 2018-02-06
CN104302315A (zh) 2015-01-21
BR112014018815A2 (sl) 2017-06-20
EP2809349A1 (en) 2014-12-10
ES2707294T3 (es) 2019-04-03
WO2013114268A1 (en) 2013-08-08
BR112014018815B1 (pt) 2022-07-12
SG11201404447WA (en) 2014-08-28
DK2809349T3 (da) 2019-02-18
JP6042455B2 (ja) 2016-12-14
KR20140123553A (ko) 2014-10-22
PT2809349T (pt) 2019-02-01
EP2809349A4 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
HK1231412A1 (zh) 免疫原性組合物
ZA201503927B (en) Immunogenic composition
SG11201404447WA (en) Immunogenic composition
PL2647387T3 (pl) Kompozycja szczepionki
IL238079A0 (en) Immunogenic preparation
SG11201500979RA (en) Immunogenic composition
PL2714910T3 (pl) Kompozycja immunogenna
GB201223342D0 (en) Immunogenic composition
GB201218660D0 (en) Immunogenic composition
GB201204968D0 (en) Immunogenic composition
GB201204851D0 (en) Immunogenic composition